期刊文献+
共找到184篇文章
< 1 2 10 >
每页显示 20 50 100
Genetic and Metabolic Determinants of Plasminogen Activator Inhibitor 1 (PAI-1) in Tunisian Type 2 Diabetes Patients 被引量:2
1
作者 Mohamed Moustapha Molka Chadhli-Chaieb +1 位作者 Touhami Mahjoub Larbi Chaieb 《Open Journal of Endocrine and Metabolic Diseases》 2017年第6期141-150,共10页
Background: PAI-1 (plasminogen activator inhibitor-1) is a powerful regulator of fibrinolysis and plasma level is high in type 2 diabetes and cardio-vascular disease, which is determined by genetic polymorphisms in PA... Background: PAI-1 (plasminogen activator inhibitor-1) is a powerful regulator of fibrinolysis and plasma level is high in type 2 diabetes and cardio-vascular disease, which is determined by genetic polymorphisms in PAI-1 gene and environmental factors. The aim of the study was to examine the determinants of plasma PAI-1 Ag level among type 2 diabetes patients. Methods: 491 Tunisian type 2 diabetes patients had clinical evaluation (weight, high, BMI, Waist Circumference), laboratory investigations including FBG Hb1Ac, cholesterol, triglyceride;HDL-cholesterol was done;plasma PAI-1 antigen level was done with ELISA;&minus;675 4G/5G and &minus;844 G/A polymorphisms of PAI-1 gene was done by PCR-ASA and PCR-RFLP respectively. Results: The mean age for our patients was 58.3 ± 10.5 years;sex-ratio = 0.92;mean PAI-1 level was 34.6 ± 21.3 ng/ml. We didn’t find correlation between PAI-1 level and BMI, but we have found significant correlation between PAI-1 and waist circumference (p = 0.032), most enhanced in men (P = 0.002), T2D patients who have FBG > 11 mmol/l had PAI-1 Ag level higher than those who have FBG P = 0.034), but no difference found between T2D with high Hb1Ac > 8% and those with Hb1Ac < 8%, significant correlation was seen between PAI-1 level and LDL-cholesterol (P = 0.05), high correlation between PAI-1 Ag level and &minus;675 4G/5G polymorphism genotype was seen, 4G/4G carriers had the highest PAI-1 level, 4G/5G had intermediary level and 5G/5G had the lowest level (P &minus;844G/A polymorphism genotypes. Using multiple variable linear regression analysis, the independent factor associated with plasma PAI-1 level was &minus;675 4G/5G polymorphism (regression coefficient β = 4.6, P Conclusion: the present study identifies &minus;675 4G/5G not &minus;844 G/A polymorphism of PAI gene as the principal determinant of plasma PAI-1 level in Tunisian T2D patients, the android fat distribution, dyslipidemia and hyperglycemia play a modest role in this variation. 展开更多
关键词 plasminogen activator inhibitor 1 POLYMORPHISM PCR type 2 Diabetes MELLITUS METABOLIC Syndrome X
下载PDF
Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator 被引量:2
2
作者 江龙光 于海洋 +5 位作者 袁彩 王俊东 陈荔清 Edward J. Meehand 黄子祥 黄明东 《Chinese Journal of Structural Chemistry》 SCIE CAS CSCD 2009年第11期1427-1432,共6页
Urokinase-type plasminogen activator (uPA) plays a crucial role in the regulation of plasminogen activation, tumor cell adhesion and migration. The inhibition of uPA activity is a promising mechanism for anti-cancer... Urokinase-type plasminogen activator (uPA) plays a crucial role in the regulation of plasminogen activation, tumor cell adhesion and migration. The inhibition of uPA activity is a promising mechanism for anti-cancer therapy. Most current uPA inhibitors employ a highly basic group (either amidine or guanidine group) to target the S1 pocket of uPA active site, which leads to poor oral bioavailability. Here we study the possibility of using less basic 2-aminobenzothiazole (ABT) as S1 pocket binding group. We report the crystal structures of uPA complexes with ABT or 2-amino-benzothiazole-6-carboxylic acid ethyl ester (ABTCE). The inhibitory constants of these two inhibitors were measured by a chromogenic competitive assay, and it was found that ABTCE is a better inhibitor for uPA (Ki = 656 μM) than ABT (Ki = 5.03 mM). This work shows that 2-amniobenzothiazole can be used as P1 group which may have better oral bioavailability than the commonly used amidine or guanidine group. We also found the ethyl ester group occupies the characteristic oxyanion hole and contacts to uPA 37- and 60-loops. Such work provides structural information for further improvements of potency and selectivity of this new class of uPA inhibitor. 展开更多
关键词 urokinase-type plasminogen activator 2-aminobenzothiazole 2-amino-benzothiazole-6-carboxylic acid ethyl ester P1 group
下载PDF
动态心电图及sST2、PAI-1在川崎病伴发冠脉损伤诊断中的研究
3
作者 陈晓光 窦冰华 《临床研究》 2024年第8期153-156,共4页
目的探讨动态心电图及可溶性人基质裂解素-2(sST2)、纤溶酶原激活物抑制物-1(PAI-1)在川崎病伴发冠脉损伤诊断中的意义。方法研究对象选取2018年1月至2024年1月郑州大学第一附属医院收治的102例川崎病患儿,根据患儿是否伴发冠脉损伤分... 目的探讨动态心电图及可溶性人基质裂解素-2(sST2)、纤溶酶原激活物抑制物-1(PAI-1)在川崎病伴发冠脉损伤诊断中的意义。方法研究对象选取2018年1月至2024年1月郑州大学第一附属医院收治的102例川崎病患儿,根据患儿是否伴发冠脉损伤分为两组,其中损伤组40例,未损伤组62例。比较两组患儿的临床病例资料[性别、年龄、身体质量指数(BMI)、发热持续时间、白细胞计数、25-羟维生素D3(25-(OH)D_(3))、血红蛋白、血小板计数、肌酸激酶同工酶(CK-MB)、氨基末端脑利钠肽前体(NT-proBNP)、C反应蛋白(CRP)、sST2、PAI-1]及动态心电图异常率,通过多因素分析川崎病伴发冠脉损伤的影响因素,绘制ROC曲线评价不同指标对川崎病患儿伴发冠脉损伤的诊断价值。结果损伤组患儿的发热持续时间、血小板计数、CRP、CK-MB、NT-proBNP、sST2、PAI-1水平高于未损伤组,25-(OH)D_(3)水平低于未损伤组,差异具有统计学意义(P<0.05)。损伤组患儿的动态心电图异常率为60.00%,未损伤组患儿的动态心电图异常率为16.13%,损伤组高于未损伤组,差异具有统计学意义(P<0.05)。二元Logistic分析结果显示,发热持续时间、25-(OH)D_(3)、血小板计数、CRP、CK-MB、NT-proBNP、sST2、PAI-1、动态心电图异常是川崎病患儿伴发冠脉损伤的影响因素(P<0.05)。以sST2、PAI-1、动态心电图异常及3项指标联合应用作为变量绘制诊断川崎病伴发冠脉损伤的ROC曲线,sST2的AUC为0.789,PAI-1的AUC为0.729,动态心电图异常的AUC为0.719,联合检测的AUC为0.978。结论动态心电图及sST2、PAI-1水平诊断川崎病是否伴发CAL具有较高的诊断价值。 展开更多
关键词 动态心电图 可溶性人基质裂解素-2 纤溶酶原激活物抑制物-1 川崎病 冠脉损伤
下载PDF
Study on Effect of Different Dosages of Ligustrazine on Level of Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes Mellitus Patients
4
作者 薛现中 张兆华 邢小燕 《Chinese Journal of Integrated Traditional and Western Medicine》 2003年第3期199-203,共5页
Objective: To observe the effect of different dosages of ligustrazine (LG) on the level of plasminogen activator inhibitor-1 (PAI-1) activity in patients with type 2 diabetes mellitus. Methods: Ninety cases of type 2 ... Objective: To observe the effect of different dosages of ligustrazine (LG) on the level of plasminogen activator inhibitor-1 (PAI-1) activity in patients with type 2 diabetes mellitus. Methods: Ninety cases of type 2 diabetes mellitus inpatients were selected, and randomly divided into LG small dosage group (SDG), LG large dosage group (LDG) and control group. The 120 mg LG, 400 mg LG and normal saline 250 ml were given through intravenous dripping respectively, once daily, 20 days as one treatment course. Before and after treatment, all the patients had their fasting blood taken for PAI-1 and tissue plasminogen activator (t-PA) assessment test to perform the comparative study. Results:Seventy-three out of the 90 patients completed the observation course, the PAI-1 activity of three groups after treatment all lowered compared with that before treatment, and the difference between groups was also significant (all P<0. 01). After treatment the PAI-1 level of SDG and LDG of LG were all markedly lowered (all P<0. 01), the LDG's lowering was more evident than that of SDG, and comparison between these two groups of patients showed significant difference (P<0. 01). Although in the control group there was some difference between before and after treatment, it was not so significant like the above-mentioned two groups (P = 0. 0140). No adverse reaction occurred in the 3 groups during the observation period. Conclusion:LG could safely and effectively lower type 2 diabetes mellitus patient's plasma PAI-1 activity level, and LDG of LG proved to be particularly effective. 展开更多
关键词 type 2 diabetes mellitus LIGUSTRAZINE plasminogen activator inhibitor-1
下载PDF
Research on the correlation of serum plasminogen activator inhibitor-1 level to vascular complications in type 2 diabetes mellitus patients with overweight or obesity
5
作者 Jun X Yanan Z +5 位作者 Zhijie C Zhihui D Danhua S Xiaojing C Ying W Jixiang J 《Discussion of Clinical Cases》 2019年第2期20-25,共6页
Objective:To explore the relationship between serum plasminogen activator inhibitor(PAI-1)level and Type 2 Diabetes Mellitus(T2DM)accompanied by overweight or obesity by observing not only the changes of PAI-1 level i... Objective:To explore the relationship between serum plasminogen activator inhibitor(PAI-1)level and Type 2 Diabetes Mellitus(T2DM)accompanied by overweight or obesity by observing not only the changes of PAI-1 level in T2DM patients with overweight or obesity,but also glucose and lipid metabolism related indicators,the changes of the inflammatory cytokines secreted by adipocytes,and then making an analysis on the correlation to PAI-1.Methods:36 cases of healthy examinees were selected as normal control group(NC group),and the experimental group can be divided into T2DM group(54 cases),Overweight/Obesity group(35 cases)and T2DM+Overweight/Obesity group(48 cases).Glucose and lipid metabolism related indicators such as fasting blood glucose(FBG),triglyceride(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),glycated hemoglobin(HbA1c),fasting insulin(FINS),insulin resistance index(IR),body weight index(BMI)and inflammatory cytokines interleukin-6(IL-6),tumor necrosis factor(TNF-α)and PAI-1 were observed and compared between groups,and then made an analysis to explore the correlation of these factors to PAI-1.Results:(1)Compared with NC group,the levels of FBG,HbA1c,FINS and IR were increased in T2DM group,and the difference was of statistical significance.However,there was no statistically significant difference in TG,TC,LDL-C and BMI between NC group and T2DM group;the levels of FINS,IR,TG,LDL-C,TC and BMI were elevated in Overweight/Obesity group,and the difference was of statistical significance.However,there was no statistically significant difference in FBG and HbA1c;the levels of FBG,HbA1c,FINS,IR,TG,LDL-C,TC and BMI were up-regulated in T2DM+Overweight/Obesity group,and the difference was of statistical significance.Compared with T2DM group,the levels of TG,TC,LDL-C and BMI were increased in Overweight/Obesity group,and the difference was of statistical significance,however,the levels of FBG,HbA1c,FINS and IR were decreased,and the difference was statistically significant;The levels of FINS,IR,TG,TC,LDL-C and BMI were elevated in T2DM+Overweight/Obesity group,and the difference was of statistical significance,however,there was no statistically significant difference in FBG and HbA1c.Compared with Overweight/Obesity group,the levels of FBG,FINS,IR,HbA1c and LDL-C were increased in T2DM+Overweight/Obesity group,and the difference was of statistical significance.However,the difference in TG,TC and BMI was not statistically significant.(2)Compared with NC group,the levels of IL-6,TNF-αand PAI-1 were increased in T2DM group,Overweight/Obesity group and T2DM+Overweight/Obesity group,and the difference was statistically significant.Compared with T2DM group,the levels of IL-6 and TNF-αwere elevated in Overweight/Obesity group,and the difference was of statistical significance,but there was no statistically significant difference in PAI-1;the levels of IL-6,TNF-αand PAI-1 were up-regulated in T2DM+Overweight/Obesity group,and the difference was statistically significant.Compared with Overweight/Obesity group,there was no statistically significant difference in IL-6 and TNF-αbetween T2DM+Overweight/Obesity group and Overweight/Obesity group,but the level of PAI-1 was increased in T2DM+Overweight/Obesity group,and the difference was of statistical significance.(3)Multivariate Logistic Regression Analysis showed that HbA1c,IR,TG,BMI,IL-6 and TNF-αwere independently associated with the level of PAI-1(all p<.05).Conclusions:(1)The level of PAI-1 is higher in type 2 diabetes mellitus patients with overweight or obesity than that in patients only with type 2 diabetes mellitus,and it is one of causes that result in vascular complications.(2)The increase in the level of PAI-1 is considered to be associated with IL-6 and TNF-αsecreted by adipocytes. 展开更多
关键词 plasminogen activator inhibitor-1 type 2 diabetes mellitus OVERWEIGHT/OBESITY
下载PDF
Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer 被引量:12
6
作者 FengJi Yue-LiangChen En-YunJin Wei-LinWang Zi-LiYang You-MingLi 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第21期3222-3226,共5页
AIM: To investigate the relationship between matrix metalloproteinase-2 (MMP-2) mRNA expression and clinicopathologic and urokinase-type plasminogen activator (uPA) system parameter and prognosis in human gastric canc... AIM: To investigate the relationship between matrix metalloproteinase-2 (MMP-2) mRNA expression and clinicopathologic and urokinase-type plasminogen activator (uPA) system parameter and prognosis in human gastric cancer.METHODS: Expression of MMP-2 mRNA, uPA, and uPA-R mRNA in tumor tissues and ≥5 cm adjacent normal tissues from 67 cases of gastric cancer was studied using RTPCR and Northern blot respectively. Survival analyses were done using the Kaplan-Meier method. RESULTS: The expression rates of MMP-2 mRNA, uPA and uPA-R mRNA in tumor tissues (31%, 41%, and 51%, respectively) were significantly higher than those in ≥5 cm adjacent tissues (19%, 11%, and 9%; χ2 = 4.59, 43.58, and 53.24 respectively, P<0.05, 0.0001, and 0.0001, respectively). Expression of MMP-2 mRNA was significantly correlated with lymph node metastasis (metastasis:61.9%, no metastasis: 39.1%, χ2= 7.61, P<0.05), Lauren's classification of diffuse/mixed types: 54.2%, intestinal type: 26.3%, χ2 = 4.25, P<0.05, expression of uPA and uPA-R mRNA (uPA+: 55.1%, uPA-: 22.2% and uPA-R+: 54.9%, uPA-R-: 18.8%, x2= 5.72 and 6.40 respectively, P<0.05). Kaplan-Meier survival analysis of MMP-2 mRNA expression did not show significant difference in all 67 cases, but revealed an association of the expression of MMP-2 mRNA, uPA, and uPA-R mRNA with worse prognosis (P = 0.0083, 0.0160, and 0.0094, respectively). CONCLUSION: MMP-2 may play an important role in the development of invasion and metastasis of gastric cancer. 展开更多
关键词 金属合酶-2 MRNA 基因表达 临床病理学 尿激酶 血浆酶原 胃癌
下载PDF
Expression of Plasminogen Activator Inhibitor-2 is Negatively Associated with Invasive Potential in Hepatocellular Carcinoma Cells
7
作者 Ye Jin Li Zhou +1 位作者 Ke-min Jin Bao-cai Xing 《Chinese Medical Sciences Journal》 CAS CSCD 2013年第1期16-19,共4页
Objective To investigate the association between plasminogen activator inhibitor(PAI)-2 expression and invasive potential in hepatocellular carcinoma(HCC) cells.Methods The HCC cell lines with high,low,and non-metasta... Objective To investigate the association between plasminogen activator inhibitor(PAI)-2 expression and invasive potential in hepatocellular carcinoma(HCC) cells.Methods The HCC cell lines with high,low,and non-metastatic potentials,namely MHCC97-H,MHCC97-L,and SMMC-7721 respectively,were cultured in vitro.Matrigel invasion assay and Western blot of PAI-2 protein expression were conducted.Results The number of invaded cells in MHCC97-L was significantly higher than that in SMMC-7721(P=0.005),whereas that in MHCC97-H was higher than in MHCC97-L(P=0.017) and SMMC-7721(P=0.001).Contrarily,PAI-2 protein expression was gradually reducing from SMMC-7721,MHCC97-L,to MHCC97-H(MHCC97-H vs.MHCC97-L,P<0.001;MHCC97-H vs.SMMC-7721,P=0.001;MHCC97-L vs.SMMC-7721,P=0.001).The Pearson's correlation analysis revealed a significant negative association between invaded cell number and PAI-2 expression(r= 0.892,P=0.001).Conclusion PAI-2 expression may be negatively associated with the invasive potential of HCC. 展开更多
关键词 纤溶酶原激活物抑制物 肝癌细胞 负相关 侵袭 抑制剂 pai-2 蛋白表达 肝细胞癌
下载PDF
Tissue-type plasminogen activator is a homeostatic regulator of synaptic function in the central nervous system 被引量:1
8
作者 Valerie Jeanneret Manuel Yepes 《Neural Regeneration Research》 SCIE CAS CSCD 2017年第3期362-365,共4页
Membrane depolarization induces the release of the serine proteinase tissue-type plasminogen activator(t PA) from the presynaptic terminal of cerebral cortical neurons.Once in the synaptic cleft this t PA promotes t... Membrane depolarization induces the release of the serine proteinase tissue-type plasminogen activator(t PA) from the presynaptic terminal of cerebral cortical neurons.Once in the synaptic cleft this t PA promotes the exocytosis and subsequent endocytic retrieval of glutamate-containing synaptic vesicles,and regulates the postsynaptic response to the presynaptic release of glutamate.Indeed,t PA has a bidirectional effect on the composition of the postsynaptic density(PSD) that does not require plasmin generation or the presynaptic release of glutamate,but varies according to the baseline level of neuronal activity.Hence,in inactive neurons t PA induces phosphorylation and accumulation in the PSD of the Ca^(2+)/calmodulin-dependent protein kinase IIα(pCa MKIIα),followed by pCa MKIIα-induced phosphorylation and synaptic recruitment of Glu R1-containing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid(AMPA) receptors.In contrast,in active neurons with increased levels of pCa MKIIα in the PSD t PA induces pCa MKIIα and p Glu R1 dephosphorylation and their subsequent removal from the PSD.These effects require active synaptic N-methyl-D-aspartate(NMDA) receptors and cyclin-dependent kinase 5(Cdk5)-induced phosphorylation of the protein phosphatase 1(PP1) at T320.These data indicate that t PA is a homeostatic regulator of the postsynaptic response of cerebral cortical neurons to the presynaptic release of glutamate via bidirectional regulation of the pCa MKIIα/PP1 switch in the PSD. 展开更多
关键词 tissue-type plasminogen activator (tPA) homeostatic plasticity Ca^2+/calmodulin-dependent protein kinase post-synaptic density protein phosphatase 1 PLASMIN
下载PDF
2型糖尿病患者t-PA、PAI-1水平及胰激肽原酶治疗后的变化 被引量:5
9
作者 孙超 尹晓 +1 位作者 蒲迎 孙金凤 《山东大学学报(医学版)》 CAS 北大核心 2008年第11期1060-1062,共3页
目的测定2型糖尿病患者纤溶酶原激活物(t-PA)、纤溶酶原激活抑制物-1(PAI-1)水平,并观察胰激肽原酶治疗后的变化。方法选取2型糖尿病患者88例,分为无血管并发症组和有血管并发症组,另设正常对照组,测量身高、体质量、血压、血糖、血脂... 目的测定2型糖尿病患者纤溶酶原激活物(t-PA)、纤溶酶原激活抑制物-1(PAI-1)水平,并观察胰激肽原酶治疗后的变化。方法选取2型糖尿病患者88例,分为无血管并发症组和有血管并发症组,另设正常对照组,测量身高、体质量、血压、血糖、血脂等指标,用酶联免疫吸附双抗体夹心法(ELISA)测定胰激肽原酶治疗前后血浆t-PA、PAI-1水平。结果两组糖尿病患者t-PA水平均低于正常对照组,PAI-1水平均高于正常对照组(P<0.05或0.01);有血管并发症组t-PA水平低于无血管并发症组,PAI-1水平高于无血管并发症组(P均<0.01)。t-PA与TG、LDL-C呈负相关(P<0.01),PAI-1与BMI、SBP、FBG、HbA1c、TG、LDL-c呈正相关(P<0.01),与HDL呈负相关(P<0.01)。两组糖尿病患者用胰激肽原酶治疗后,PAI-1水平下降,t-PA水平升高。结论糖尿病患者血浆t-PA水平降低,PAI-1水平升高,尤其是伴有血管并发症者变化更明显,胰激肽原酶治疗后,可改善t-PA和PAI-1水平的异常变化。 展开更多
关键词 糖尿病 非胰岛素依赖型 纤溶酶原激活剂 纤溶酶原激活物抑制物 胰激肽原酶
下载PDF
人纤溶酶原激活剂抑制物2型(PAI-2)在大肠杆菌中的表达和分离纯化 被引量:3
10
作者 田昱 沈俊卿 +2 位作者 李平 宋后燕 朱运松 《中国生物化学与分子生物学报》 CAS CSCD 1998年第5期536-541,共6页
用PCR方法从pPAIJ.7中扩增人纤溶酶原激活剂抑制物2型(PAI-2)cDNA,与pUC18重组,经限制性内切酶片段分析与核苷酸序列分析,获得全长人PAI-2cDNA.PAI-2cDNA与原核表达载体重组,构建原... 用PCR方法从pPAIJ.7中扩增人纤溶酶原激活剂抑制物2型(PAI-2)cDNA,与pUC18重组,经限制性内切酶片段分析与核苷酸序列分析,获得全长人PAI-2cDNA.PAI-2cDNA与原核表达载体重组,构建原核表达质粒并转化大肠杆菌.经温度诱导表达,重组PAI-2占全菌总蛋白的14%,以可溶性形式存在,具纤溶抑制活性.工程菌发酵、压榨后,用硫酸铵分级沉淀,沉淀物经分子筛、离子交换和疏水性色谱的分离,每升菌液可获得约30mg纯度达90%的蛋白质,比活性为11866AIU/mg蛋白质,得率为19.2%. 展开更多
关键词 原核表达 分离纯化 pai-2 大肠杆菌
下载PDF
正常妊娠妇女和妊娠期高血压疾病患者血浆TAFI和PAI-2变化的研究 被引量:5
11
作者 张迎红 胡豫 +5 位作者 郭涛 魏文宁 赵云 张小平 王华芳 梅恒 《中国妇幼保健》 CAS 北大核心 2008年第18期2493-2495,共3页
目的:探讨凝血酶活化的纤维蛋白溶解抑制物(TAFI)和纤维酶原激活抑制物-2(PAI-2)在正常妊娠妇女和妊娠高血压疾病患者血浆中的变化及其临床意义。方法:研究对象包括22例妊娠期高血压疾病患者(其中子痫前期10例、妊娠期高血压12例)、30... 目的:探讨凝血酶活化的纤维蛋白溶解抑制物(TAFI)和纤维酶原激活抑制物-2(PAI-2)在正常妊娠妇女和妊娠高血压疾病患者血浆中的变化及其临床意义。方法:研究对象包括22例妊娠期高血压疾病患者(其中子痫前期10例、妊娠期高血压12例)、30例正常妊娠妇女和30例正常未孕妇女,应用酶联免疫吸附试验(ELISA)测定研究对象妊娠早、中、晚三期血浆中的TAFI和PAI-2抗原水平。结果:与未孕对照组比较,正常妊娠组妊娠各期PAI-2均明显升高,差异均有显著统计学意义(P均<0.01),而TAFI在孕晚期才明显高于未孕组,差异有统计学意义(P<0.05),与正常妊娠组比较,妊娠期高血压组妊娠三期中TAFI、PAI-2抗原水平差异无统计学意义(P>0.05),子痫前期组妊娠三期TAFI明显高于正常妊娠组,而PAI-2均低于正常妊娠组,差异均具有统计学意义(P<0.05)。结论:TAFI、PAI-2在正常妊娠妇女发挥着纤溶抑制作用,维持母体凝血和纤溶的平衡。TAFI是一个预测子痫前期的敏感指标,有助于预测子痫前期患者血栓前状态的形成,而PAI-2不能用来判断母体内纤溶水平变化,但可能预示不良妊娠结局。两者对于妊娠期高血压患者的临床意义不大。 展开更多
关键词 妊娠期高血压疾病 纤维酶原激活抑制物-2 凝血酶活化的纤维蛋白溶解抑制物
下载PDF
tPA Involvement in Ovulation──Studies on Mechanism of Ovulation:Role of Tissue Type Plasminogen Activator
12
作者 LIU Yi-xun(State Key Laboratory of Reproductive Biology,Institute of Zoology,Chinese Academy of Sciences, Beijing 100080) 《Developmental and Reproductive Biology》 1994年第2期70-78,共9页
tPAInvolvementinOvulation──StudiesonMechanismofOvulation:RoleofTissueTypePlasminogenActivatorLIUYi-xun(State... tPAInvolvementinOvulation──StudiesonMechanismofOvulation:RoleofTissueTypePlasminogenActivatorLIUYi-xun(StateKeyLaboratoryofRe... 展开更多
关键词 排卵过程 TPA pai-1 作用
下载PDF
PAI-1基因多态与中国人2型糖尿病肾病的相关性 被引量:4
13
作者 郑泰山 刘丽梅 +4 位作者 周文锐 李鸣 徐靖 陆惠娟 项坤三 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2007年第7期774-776,共3页
目的探讨纤溶酶原激活物抑制因子-1(PAI-1)基因多态与上海地区中国人2型糖尿病肾病的相关性。方法选取2型糖尿病(T2DM)患者247例组成T2DM组,其进一步分为糖尿病无肾病组(n=80)和糖尿病肾病组(n=167),后者又分为微量蛋白尿肾病组(n=129)... 目的探讨纤溶酶原激活物抑制因子-1(PAI-1)基因多态与上海地区中国人2型糖尿病肾病的相关性。方法选取2型糖尿病(T2DM)患者247例组成T2DM组,其进一步分为糖尿病无肾病组(n=80)和糖尿病肾病组(n=167),后者又分为微量蛋白尿肾病组(n=129)和显著蛋白尿肾病组(n=38);同时设立非糖尿病对照组(n=87)。应用等位基因特异性PCR法(ASP法)检测PAI-1基因启动子区——675 bp处的4G/5G多态,确定各组PAI-1基因的基因型。采用χ2检验对组间各基因型频率及等位基因频率进行比较,并比较组间携带纯合子风险等位基因4G/4G的基因型频率差异。结果T2DM组与非糖尿病对照组相比,4G/4G基因型及4G等位基因频率无统计学差异(P>0.05)。与糖尿病无肾病组相比,糖尿病肾病组4G/4G基因型频率显著增加(P<0.01,OR=2.4,95%C I=1.3~4.4),4G等位基因频率亦显著增加(P<0.05,OR=1.6,95%C I=1.1~2.3)。结论PAI-1基因多态与中国人T2DM无肾病患者进展为糖尿病肾病显著相关;携带PAI-1基因的4G/4G纯合子基因型的糖尿病患者,其进展为糖尿病蛋白尿肾病的风险增加2.4倍。 展开更多
关键词 2型糖尿病 糖尿病肾病 纤溶酶原激活物抑制因子-1 4G/5G多态
下载PDF
PAI-1基因启动区4G/5G多态性与2型糖尿病并发脑梗死的关系 被引量:3
14
作者 郭晖 杜丹华 +2 位作者 高鹏 孙明 赵节绪 《中风与神经疾病杂志》 CAS CSCD 北大核心 2006年第4期452-455,共4页
目的研究PAI-1基因启动区4G/5G多态性在中国北方汉族人2型糖尿病(DM)患者及并发脑梗死(CI)患者中的分布,以及各组中血浆PAI-1抗原水平的变化。方法将280名受试对象分为4组:健康对照组(92例)、非DM脑梗死组(60例)、单纯DM组(88例)及DM并... 目的研究PAI-1基因启动区4G/5G多态性在中国北方汉族人2型糖尿病(DM)患者及并发脑梗死(CI)患者中的分布,以及各组中血浆PAI-1抗原水平的变化。方法将280名受试对象分为4组:健康对照组(92例)、非DM脑梗死组(60例)、单纯DM组(88例)及DM并发CI组(40例)。全部受试对象均需应用ELISA法测定血浆PAI-1抗原水平,等位基因特异性引物PCR扩增技术测PAI-1基因启动区4G/5G多态性。结果DM、CI患者血浆PAI-1抗原水平显著升高,中国北方汉族人中,DM组中脑梗死患者5G等位基因频率和5G/5G基因型频率不仅显著高于健康对照组,也显著高于DM无脑梗死组和无DM脑梗死组。在DM组中,5G纯合子携带者发生CI的风险增加3.81倍,有统计学意义。结论PAI-1启动区5G/5G基因型是2型DM患者中CI高发的易感基因型之一。 展开更多
关键词 2型糖尿病 脑梗死 纤溶酶原激活物抑制因子-1 聚合酶链反应 多态性
下载PDF
人纤溶酶原激活剂抑制物2型(PAI-2)在Pichia pastoris中的表达 被引量:2
15
作者 田昱 李平 朱运松 《中国生物化学与分子生物学报》 CAS CSCD 1998年第3期258-263,共6页
用PCR方法从pPAIJ.7中扩增人纤溶酶原激活剂抑制物2型(PAI-2)基因,与pPUC18重组,经限制性内切酶片段分析与核苷酸序列分析,获得全长人PAI-2基因.PAI-2基因与表达载体pPIC9重组,构建受乙醇... 用PCR方法从pPAIJ.7中扩增人纤溶酶原激活剂抑制物2型(PAI-2)基因,与pPUC18重组,经限制性内切酶片段分析与核苷酸序列分析,获得全长人PAI-2基因.PAI-2基因与表达载体pPIC9重组,构建受乙醇氧化酶1基因(AOX1)启动子与转录终止区控制的酵母表达质粒,转化GS115宿主菌,经表型筛选和PCR扩增筛选阳性克隆,用甲醇诱导表达,重组PAI-2以分泌型表达,占分泌总蛋白的30%,具PAI-2抗原性,与低分子量尿激酶形成了抗SDS复合物,具抑制纤溶的活性(91.4AIU/ml).对培养条件也进行了探讨. 展开更多
关键词 纤溶酶原激活剂 抑制物2 酵母表达 PCR
下载PDF
PAI-1基因4G/5G多态性与2型糖尿病肾病相关性 被引量:5
16
作者 刘梦阳 杨忠思 +2 位作者 申黎艳 孙士营 李慧 《青岛大学医学院学报》 CAS 2011年第1期31-32,35,共3页
目的探讨PAI-1基因4G/5G多态性与2型糖尿病(2DM)肾病(DN)的相关性,寻找DM的致病基因。方法采用等位基因特异性引物PCR扩增技术检测39例正常人(对照组)和63例2DM病人PAI-1基因4G/5G多态性。结果 DN组PAI-1基因型频率和等位基因频率与对... 目的探讨PAI-1基因4G/5G多态性与2型糖尿病(2DM)肾病(DN)的相关性,寻找DM的致病基因。方法采用等位基因特异性引物PCR扩增技术检测39例正常人(对照组)和63例2DM病人PAI-1基因4G/5G多态性。结果 DN组PAI-1基因型频率和等位基因频率与对照组比较差异均有显著性(χ2=12.186、7.446,P<0.05),DM组PAI-1基因型频率和等位基因频率与对照组比较差异均有显著性(2χ=24.127、7.312,P<0.05);DN组、DM组4G等位基因频率明显高于对照组,差异有显著性(χ2=6.280,P<0.05)。DN组4G/4G、4G/5G、5G/5G基因型病人尿微量清蛋白排泄率比较差异均有显著性(F=4.922,P<0.05)。结论 4G等位基因存在时,DM的发病风险明显增高,4G等位基因是病人出现清蛋白尿的危险因素。 展开更多
关键词 纤溶酶原激活物抑制物1 基因型 基因频率 糖尿病 2 糖尿病肾病
下载PDF
大肠杆菌表达的重组人PAI-2的纯化及其生物化学特性 被引量:2
17
作者 田昱 沈俊卿 +3 位作者 蔡晓燕 李平 宋后燕 朱运松 《上海医科大学学报》 CSCD 1998年第3期163-166,共4页
目的研究建立大肠杆菌表达的重组人PAI-2(rhPAI-2)的纯化方法,并对rhPAI-2蛋白进行理化和生物学性质的研究。方法工程菌被高压匀浆后,经硫酸铵分级沉淀,用分子筛、离子交换和疏水性色谱进行分离,得到了rhP... 目的研究建立大肠杆菌表达的重组人PAI-2(rhPAI-2)的纯化方法,并对rhPAI-2蛋白进行理化和生物学性质的研究。方法工程菌被高压匀浆后,经硫酸铵分级沉淀,用分子筛、离子交换和疏水性色谱进行分离,得到了rhPAI-2蛋白。对rhPAI-2进行了复性,对rhPAI-2的温度、pH、盐浓度、氧化剂敏感性、二级速率常数及抗SDS复合物形成等理化性质和生物学特性进行了测定。结果每升菌液可获得约30mg纯度达90%的蛋白质,比活性为11866AIU/mg,得率为19.2%。当温度高至60℃时,rhPAI-2迅速失活;当pH小于3时,rhPAI-2完全失活;当盐浓度和H2O2浓度分别在1.5和0.5mol/L时,rhPAI-2的活性仍维持在90%以上;rhPAI-2可与尿激酶形成抗SDS复合物。结论成功地从大肠杆菌中分离纯化了rhPAI-2。rhPAI-2与天然PAI-2在理化性质和生物学特性上基本一致。 展开更多
关键词 分离 纯化 大肠杆菌 pai-2 生物化学性
下载PDF
不饱和脂肪酸影响HepG-2细胞PAI-1表达的机制初探 被引量:2
18
作者 贺艳丽 叶平 +3 位作者 周新 方红 王琼 刘永学 《中国病理生理杂志》 CAS CSCD 北大核心 2005年第3期436-440,共5页
目的 :探讨不饱和脂肪酸对HepG - 2细胞纤溶酶原激活物抑制剂 - 1(PAI- 1)表达的影响及其机制。方法 :以发色底物法检测PAI- 1活性 ,RT -PCR法检测PAI- 1mRNA水平 ;构建两个含不同片段缺失的PAI- 1启动子序列控制表达的氯霉素转移乙酰酶... 目的 :探讨不饱和脂肪酸对HepG - 2细胞纤溶酶原激活物抑制剂 - 1(PAI- 1)表达的影响及其机制。方法 :以发色底物法检测PAI- 1活性 ,RT -PCR法检测PAI- 1mRNA水平 ;构建两个含不同片段缺失的PAI- 1启动子序列控制表达的氯霉素转移乙酰酶 (CAT)报告基因质粒 ,转染HepG - 2细胞 ,ELISA法检测CAT表达量。结果 :油酸、亚油酸诱导下HepG - 2细胞PAI- 1mRNA表达及蛋白活性显著高于对照组 ;共转染过氧化体增殖物激活型受体表达质粒 (PPARα -pSG5 )PAI- 1转录活性显著增加 ;转染NF -κB样蛋白结合序列缺失的重组质粒 ,亚油酸诱导下PAI- 1转录活性显著增加 ,而转染VLDL/脂肪酸反应元件缺失的重组质粒则无显著变化。结论 :不饱和脂肪酸增强HepG - 2细胞PAI- 1mRNA表达及活性 ;PPARα可能是其上调PAI- 1表达所涉及的转录因子之一 ,且VLDL/脂肪酸反应元件在该调控中具有重要作用 ,但可能并不涉及NF -κB信号转导途径。 展开更多
关键词 脂肪酸类 不饱和 纤溶酶原激活物抑制物1 HEPG-2细胞
下载PDF
过氧化体增殖物激活型受体激活物对HepG-2细胞PAI-1表达的影响 被引量:1
19
作者 贺艳丽 周新 +4 位作者 叶平 方红 刘永学 罗成华 王琼 《中国应用生理学杂志》 CAS CSCD 北大核心 2003年第3期298-301,共4页
目的 :观察不同的过氧化体增殖物激活型受体 (peroxisomeproliferator activatedreceptors,PPARs)激活物对HepG 2细胞纤溶酶原激活物抑制剂 1 (plasminogenactivatorinhibitor 1 ,PAI 1 )mRNA表达及其活性的影响 ,探讨过氧化体增殖物... 目的 :观察不同的过氧化体增殖物激活型受体 (peroxisomeproliferator activatedreceptors,PPARs)激活物对HepG 2细胞纤溶酶原激活物抑制剂 1 (plasminogenactivatorinhibitor 1 ,PAI 1 )mRNA表达及其活性的影响 ,探讨过氧化体增殖物激活型受体在PAI 1基因调控中的作用。方法 :分别利用硬脂酸、油酸、亚油酸、非诺贝特、吡格列酮作为诱导因素刺激HepG 2细胞 ,采用半定量RT PCR法检测PAI 1mRNA及PPARsmRNA的转录水平 ,比色法检测PAI 1活性变化 ,Westernblot法检测PPARs蛋白表达情况。结果 :与对照组比较 ,油酸、亚油酸组HepG 2细胞PAI 1mRNA表达及蛋白活性显著增加 ;非诺贝特组HepG 2细胞PAI 1mRNA表达及活性显著降低 ;硬脂酸、吡格列酮组HepG 2细胞PAI 1mRNA表达及蛋白活性均无显著变化 ;各组PPARs在mRNA及蛋白水平均无明显差异。结论 :PPARs激活物对HepG 2细胞PAI 1mRNA表达及其活性具有调节作用 ,PPARα可能是实现该调节作用的重要途径之一 ,同时不排除其他调控因素介入该调节过程。 展开更多
关键词 过氧化体增殖物激活型受体 激活物 HEPG-2细胞 pai-1 表达 凝血系统
下载PDF
PAI-1、肿瘤坏死因子α与2型糖尿病肾病的关系 被引量:3
20
作者 万惠 姚伟峰 +2 位作者 钱铁镛 黄雌友 陈一丁 《齐齐哈尔医学院学报》 2010年第2期178-180,共3页
目的探讨2型糖尿病肾病(DN)患者血中PAI-1、TNF-α等与该疾病的相关性??法选择2型糖尿病100例,其中正常白蛋白尿组36例,微量白蛋白尿组34例,大量白蛋白尿组30例,及正常对照组30例,测定其尿蛋白排泄率(UAER)、PAI-1、TNF-α等指标?峁... 目的探讨2型糖尿病肾病(DN)患者血中PAI-1、TNF-α等与该疾病的相关性??法选择2型糖尿病100例,其中正常白蛋白尿组36例,微量白蛋白尿组34例,大量白蛋白尿组30例,及正常对照组30例,测定其尿蛋白排泄率(UAER)、PAI-1、TNF-α等指标?峁≡缙贒N组和临床DN组血清TNF-α、PAI-1水平显著高于DM组(P<0.05或P<0.01),临床DN组血清TNF-α、PAI-1水平显著高于早期DN组(P<0.05或P<0.01);Pearson相关分析和多元线性回归分析表明,UAER和糖尿病的病程、TNF-α、Scr、PAI-1呈正相关(P<0.05或P<0.01)。直线相关分析显示:TNF-α与PAI-1呈正相关(r=0.452,P<0.05)。结论2型糖尿病患者TNF-α、PAI-1水平的高低与糖尿病肾病的病变阶段密切相关;PAI-1、TNF-α等因素的协同作用可能导致糖尿病肾病的发生与发展。 展开更多
关键词 纤溶酶原激活物抑制物1 肿瘤坏死因子-Α 糖尿病 2 糖尿病肾病
下载PDF
上一页 1 2 10 下一页 到第
使用帮助 返回顶部